The TPL2 overexpression rate in the FCC group was 43.3% (13/30), which was not statistically different from that of the Normal group, but it was significantly lower than those of DCIS and IDC groups. This evidence concerns the gene MAP3K8 and ductal breast carcinoma in situ.